Carbamazepine Retard 400 mg Focus Care
As listed in the register: Carbamazepine Retard 400 mg Focus Care, tabletten met gereguleerde afgifte
400 mg · tablet met gereguleerde afgifte
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Carbamazepine
- Made by
- Focus Care Pharmaceuticals B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (CARBAMAZEPINE). It describes the substance, not this exact product.
Carbamazepine has demonstrated anticonvulsant properties in rats and mice with electrically and chemically induced seizures.
It appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation.
Carbamazepine is metabolized in the liver.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-28
Safety of the active substance
From the US prescribing label for the same active substance (CARBAMAZEPINE). It describes the substance, not this exact product.
WARNINGS SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH CARBAMAZEPINE.
- Carbamazepine should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyclic compounds, such as amitriptyline, desipramine, imipramine, protriptyline, nortriptyline, etc.
- Likewise, on theoretical grounds its use with monoamine oxidase (MAO) inhibitors is not recommended.
- Before administration of carbamazepine, MAO inhibitors should be discontinued for a minimum of 14 days, or longer if the clinical situation permits.
- Coadministration of carbamazepine and nefazodone may result in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect.
The most frequently observed adverse reactions, particularly during the initial phases of therapy, are dizziness, drowsiness, unsteadiness, nausea, and vomiting.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States22 matching products
Spain3 matching products
Canada3 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Focus Care Pharmaceuticals B.V. |
|---|---|
| Active substance | Carbamazepine |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 400 mg |
| Form | tablet met gereguleerde afgifte |
| Classification | N03AF01 · Pain, sleep, mood, epilepsy and the brain |
| Route | oraal gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| Name in the register | Carbamazepine Retard 400 mg Focus Care, tabletten met gereguleerde afgifte |
| RVG | 128680 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.